Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales

Immuron Limited (NASDAQ:IMRN) is one of the best performing ASX stocks in 2025. The company released its annual report for 2025 on September 25, in which it reported a 49% growth in global revenue for fiscal year 2025. It stated that much of the growth was due to robust sales of its flagship traveler’s diarrhea product, Travelan. North American sales for Travelan increased by 76% to A$2 million, attributed to Amazon and Canadian retail growth. Australian sales rose 40% to AU$5.3 million, aided by new pharmacy channels.

The company’s net loss for the financial year reduced 24% year-over-year to AU$5.25 million. And loss per share was also better than FY2024’s: A$0.023 for FY2025, compared to AU$0.03. Gross margins for the year remained robust at 65.4%. At year-end, Immuron held AU$2.83 million in cash, down from AU$11.66 million the previous year. Shareholders’ equity stood at AU$8 million, compared to AU$12.7 million in 2024. And there was no significant long-term debt on the balance sheet; total debt remained minimal.

Immuron Limited (NASDAQ:IMRN) is one of Australia’s largest biopharmaceutical companies. It specializes in orally delivered targeted polyclonal antibodies for gastrointestinal and infectious diseases. Its flagship product is Travelan.

While we acknowledge the potential of IMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Conservative Stock Portfolio: 11 Best Stocks to Buy Now and 10 Best Performing Penny Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.